GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo

British Journal of Pharmacology

Volumn 161, Issue 1, 2010, Pages 207-228

  Behm, D J ^a   Aiyar, N V ^a   Olzinski, A R ^a   McAtee, J J ^a   Hilfiker, M A ^a   Dodson, J W ^a   Dowdell, S E ^a   Wang, G Z ^a   Goodman, K B ^a   Sehon, C A ^a   Harpel, M R ^a   Willette, R N ^a   Neeb, M J ^a   Leach, C A ^a   Douglas, S A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

antagonist; biochemical efficiency; blood pressure; dissociation rate; G protein coupled receptor; GSK1440115; GSK1562590; residence time; urotensin II; UT

Indexed keywords

GSK 1440115; GSK 1562590; ION CHANNEL; KAPPA OPIATE RECEPTOR AGONIST; RADIOLIGAND; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UROTENSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOASSAY; CAT; CLINICAL EFFECTIVENESS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; EX VIVO STUDY; FEMALE; HEMODYNAMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MALE; MONKEY; MOUSE; NEUROTRANSMITTER UPTAKE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ARTERIES; BENZAMIDES; BENZOIC ACIDS; BENZOXAZINES; CATS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HAPLORHINI; HUMANS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, KAPPA; TACHYKININS; UROTENSINS; VASOCONSTRICTION;

EID: 77955823424     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00889.x     Document Type: Article

References (45)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM et al. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 : 282 286.
3. 1 receptor. Eur J Pharmacol 449 : 229 237.
4. Behm DJ, Doe CP, Johns DG, Maniscalco K, Stankus GP, Wibberley A et al. (2004). Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 369 : 274 280.
5. Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ et al. (2006). The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. Br J Pharmacol 148 : 173 190.
6. Behm DJ, McAtee JJ, Dodson JW, Neeb MJ, Fries HE, Evans CA et al. (2008). Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br J Pharmacol 155 : 374 386.
7. 50) of an enzymatic reaction. Biochem Pharmacol 22 : 357 366.
8. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W et al. (2004). Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311 : 204 212.
9. Clozel M, Hess P, Qiu C, Ding SS, Rey M (2006). The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316 : 1115 1121.
10. Copeland RA, Pompliano DL, Meek TD (2006). Drug-target residence time and its implication for lead optimization. Nat Rev Drug Discov 5 : 730 739.
11. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV et al. (2000). Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 : 1262 1274.
12. Douglas SA, Dhanak D, Johns DG (2004a). From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 : 76 85.
13. Douglas SA, Naselsky D, Ao Z, Disa J, Herold CL, Lynch F et al. (2004b). Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 142 : 921 932.
14. Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP et al. (2005). Non-peptidic Urotensin-II Receptor (UT) Antagonists I: in vitro pharmacological characterisation of SB-706375. Br J Pharmacol 145 : 620 635.
15. Fierens FL, Vanderheyden PM, De Backer JP, Vauquelin G (1999). Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol 372 : 199 206.
16. Furchgott RF (1966). The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 3 : 21 55.
17. Gaddum JH, Hameed KA, Hathway DE, Stephens FF (1955). Quantitative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol 40 : 49 74.
18. Gong H, Wang YX, Zhu YZ, Wang WW, Wang MJ, Yao T et al. (2004). Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. J Appl Physiol 97 : 2228 2235.
19. Grieco P, Carotenuto A, Campiglia P, Gomez-Monterrey I, Auriemma L, Sala M et al. (2009). New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide. J Med Chem 52 : 3927 3940.
20. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T (2002). Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 : 767 772.
21. Ishiguro M (2004). Ligand-binding modes in cationic biogenic amine receptors. Chembiochem 5 : 1210 1219.
22. Itoh H, Itoh Y, Rivier J, Lederis K (1987). Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol Regul Integr Comp Physiol 252 : R361 R366.
23. Jenkinson DH (1996). Classical approaches to the study of drug-receptor interactions. In : Foreman JC, Johansen T (eds). Textbook of Receptor Pharmacology. CRC Press : Boca Raton, FL, pp. 47 49.
24. Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, Shankley NP (1998). Terms and symbols in quantitative pharmacology. In : Girdlestone D (ed.). The IUPHAR Compendium of Receptor Characterization and Classification. IUPHAR Media : London, pp. 6 20.
25. Ji TH, Grossmann M, Ji I (1998). G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J Biol Chem 273 : 17299 17302.
26. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L et al. (2004). Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 : 238 250.
27. Kenakin T (2006). Orthosteric drug antagonism. In : A Pharmacology Primer: Theory, Applications, and Methods. Academic Press : Massachusetts, pp. 114 119.
28. Laciurciére Y, Asmar RA (1999). A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose in truly hypertensive patients. Am J Hypertens 12 : 1181 1187.
29. Lew MJ, Angus JA (1997). An improved method for analysis of competitive agonist/antagonist interactions by non-linear regression. Ann NY Acad Sci 812 : 179 181.
30. Liu JC, Chen CH, Chen JJ, Cheng TH (2009). Urotensin II induces rat cardiomyocyte hypertrophy via the transient oxidization of Src homology 2-containing tyrosine phosphatase and transactivation of epidermal growth factor receptor. Mol Pharmacol 76 : 1186 1195.
31. McAtee JJ, Dodson JW, Dowdell SE, Erhard K, Girard GR, Goodman KB et al. (2008). Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles. Bioorg Med Chem Lett 18 : 3716 3719.
32. Maillard MP, Perregaux C, Centeno C, Stangier J, Wienen W, Brunner HR et al. (2002). In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 302 : 1089 1095.
33. Maryanoff BE, Kinney WA (2010). Urotensin-II receptor modulators as potential drugs. J Med Chem 53 : 2695 2708.
34. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG (2004). Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18 : 2344 2354.
35. Quaile MP, Kubo H, Kimbrough CL, Douglas SA, Margulies KB (2009). Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium. Circ Heart Fail 2 : 39 46.
36. Rang HP (1966). The kinetics of action of acetylcholine antagonists in smooth muscle. Proc R Soc Lond B Biol Sci 164 : 488 510.
37. Russell FD, Molenaar P, O'Brien DM (2001). Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 : 5 9.
38. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krawhenbuehl S et al. (2006). Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80 : 246 256.
39. Sidharta PN, Van Giersbergen PLM, Dingemanse J (2009). Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in healthy male subjects. J Clin Pharmacol 49 : 1168 1175.
40. Silvestre RA, Rodríguez-Gallardo J, Egido EM, Marco J (2001). Inhibition of insulin release by urotensin II - a study on the perfused rat pancreas. Horm Metab Res 33 : 379 381.
41. Song W, Ashton N, Balment RJ (2003). Effects of single bolus urotensin II injection in anaesthetized rats. J Physiol 552P : P107.
42. Swinney DC (2004). Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 3 : 801 808.
43. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F et al. (2003). Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 : 246 253.
44. Van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJG (2002). Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 19 : 639 644.
45. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P et al. (2003). Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285 : F792 F798.